Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 9/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HTR1E | P28566 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.44 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.43 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.43 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4400416 | 0.80 | SIGMAR1 (0.48) | MEN1KMT2ACACNA2D1CACNA1BCACNB1 | |
| SCHEMBL11084994 | 0.79 | CHRM3 (0.70) | CHRM3MEN1LMNAMAPTHTR1E | |
| SCHEMBL11083565 | 0.78 | CHRM3 (0.71) | CHRM3MEN1LMNAMAPTHTR1E | |
| SCHEMBL4390822 | 0.78 | POLB (0.55) | CHRM3MEN1LMNAKMT2ASIGMAR1 | |
| SCHEMBL67619 | 0.72 | HTR1E (0.60) | CHRM3MEN1LMNAMAPTHTR1E | |
| SCHEMBL28486184 | 0.72 | HTR1E (0.60) | CHRM3MEN1LMNAMAPTHTR1E | |
| SCHEMBL13114874 | 0.71 | CACNA2D1 (0.50) | CHRM3MEN1LMNAMAPTHTR1E | |
| SCHEMBL4678502 | 0.70 | SLC6A3 (0.60) | CHRM3MEN1LMNAMAPTHTR1E | |
| SCHEMBL5049598 | 0.70 | HTR1E (0.57) | CHRM3MEN1LMNAMAPTHTR1E | |
| SCHEMBL8365416 | 0.69 | HTR1E (0.61) | MEN1LMNAMAPTHTR1EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306134-A1 | Muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-12-10 | — | — | US | disclosed |
| US-7456203-B2 | Muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20040110229-A1 | Muscarinic receptor antagonists | PNC BANK, NATIONAL ASSOCIATION | 2004-06-10 | — | — | US | disclosed |
| US-6693202-B1 | MULTIBINDING LIGANDS CONTAINING SUCH AS AMINE, AMIDE, ESTER, HYDROXYL, CARBAMATE, UREA AND/OR IMINO FUNCTIONALITY | THERAVANCE, INC. | 2004-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110229-A1 | Muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | CHRM3 1/4885MEN1 3774/4885LMNA 4772/4885 |
| US-20090306134-A1 | Muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | CHRM3 1/4885MEN1 3774/4885LMNA 4772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.